

Supplemental Material

Supplemental Table 1. Antiarrhythmic drug burden over time

	Baseline	6 months	1 year	2 years	3 years	Annual change (95% CI)	P-value
	(N=20)	(N=20)	(N=20)	(N=20)	(N=19)		
Antiarrhythmic drug summary measures							
Number of DDDs, median [25 th -75 th percentile]	1.0 [0.5-1.3]	1.0 [0.5-1.1]	0.8 [0.5-1.0]	0.9 [0.3-1.0]	0.5 [0.3-1.0]	-12.5% (-28.4%, 6.9%)	0.19
Number of antiarrhythmic drugs, median [25 th -75 th percentile]	1 [1.0-1.3]	1.0 [1.0-1.0]	1.0 [1.0-1.0]	1.0 [1.0-1.0]	1.0 [1.0-1.0]	-7.2% (-21.6%, 9.9%)	0.39
Individual classes of antiarrhythmic drugs							
Class I, n (%)	3 (15.0)	3 (15.0)	3 (15.0)	3 (15.0)	1 (5.3)		
Class II, n (%)	6 (30.0)	5 (25.0)	5 (25.0)	6 (30.0)	6 (31.6)		
Class III, n (%)	13 (65.0)	12 (60.0)	13 (65.0)	9 (45.0)	9 (47.4)		
Class IV, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)		
Glycosides, n (%)	2 (10.0)	2 (10.0)	2 (10.0)	2 (10.0)	2 (10.5)		

CI, Confidence Interval. DDD, Defined Daily Dosage.